RE: Edison Report16 Jun 2016 19:10
Furthermore HMP is well placed to tap into compounds that demonstrate only equivalence to the existing globally-marketed compounds by developing these for sale by its Commercial Platform unit for the domestic Chinese market.
Importantly the China-based prescription platform will be invaluable once the R&D pipeline comes to fruition and will enable rapid commercialization of products once regulatory approved in China.
Hutchison MediPharma was one of the first tenants in Zhang Jiang, in 2002, in what has become the center of the Chinese biotech industry.
HCM is likely to seek approval for at least three compounds under the US FDA breakthrough therapy designation. This includes savolitinib for papillary renal cell carcinoma, non-small cell lung cancer and gastric cancer, sulfatinib for neuroendocrine tumors and epitinib for non-small cell lung cancer with brain metastasis.
According to Frost and Sullivan, in 2014 the value of the global oncology drug market was $102bn, while the oncology market in China alone was $11bn.
For example, the combination of savolitinib with AstraZeneca’s Tagrisso could shut down two resistant pathways accounting for 60-70% of all EGFRm+ TKI resistant NSCLC patients.
Notably the collaboration with AstraZeneca has resulted in the addition of Savolitinib to AstraZeneca’s Tagrisso and Iressa in two separate Phase Ib trials to address the opportunity for combination therapy as second- and third-line treatment for NSCLC
Lilly has enabled HCM to establish a manufacturing facility in Suzhou, China, which is currently producing Phase III clinical supplies and will on approval be used to produce fruquintinib for commercial supply.
Early Phase I data in China demonstrated sulfatinib has highly promising activity in neuroendocrine tumors, achieving an objective response rate (ORR) of 44.4% in 18 evaluable NET patients with 100% disease control rate (meaning no progression of disease)
Over the past 16 years, HCM has built a broad OTC and Rx (prescription-only drugs) TCM fully integrated, manufacturing, marketing and distribution network that reaches across China. This extensive commercial network consists of 3,200-person sales team; including 1900 medical reps for prescription drugs, 1,300 OTC sales reps covering greater than 300 cities and towns detailing to ~80,000 doctors across ~16,500 hospitals.
Those are the highlights for me as far as I have read.
Sign In
Follow the stocks
